Involvement of SOX-9 and FGF-23 in RUNX-2 Regulation in Osteoarthritic Chondrocytes

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2010 Mar 4

PMID 20196777

Citations 37

Authors

Timoklia Orfanidou

Dimitrios Iliopoulos

Konstantinos N Malizos

Aspasia Tsezou

Affiliations

Soon will be listed here.

Abstract

Chondrocytes' hypertrophy includes metabolic changes, matrix remodelling, proliferation and apoptosis, characteristics associated with the progression of osteoarthritis. We investigated a possible association among Runt-related transcription factor 2 (RUNX-2), SOX-9 and fibroblast growth factor (FGF)-23 mRNA expressions in articular chondrocytes in order to elucidate their contribution in the osteoarthritic hypertrophic cartilage. SOX-9, FGF-23, RUNX-2 and matrix metalloproteinase (MMP)-13 mRNA expressions were evaluated in osteoarthritic and normal chondrocytes by real-time PCR whereas MMP-13 protein expression by immunofluorescense. RUNX-2, FGF-23 and SOX-9 were down-regulated using small interfering RNA technology and transfection with liposomes. The effect of human recombinant FGF-23 (hrFGF-23) on SOX-9 and RUNX-2 expression was tested in normal chondrocytes. We found higher expression of RUNX-2 and FGF-23 and a decreased expression of SOX-9 mRNA in osteoarthritic chondrocytes compared to normal (P < 0.0001). RUNX-2 down-regulation resulted in reduced MMP-13 expression in osteoarthritic chondrocytes and inhibition of SOX-9 in increased RUNX-2 and MMP-13 mRNA expression in normal chondrocytes, whereas inhibition of FGF-23 resulted in reduced RUNX-2 mRNA expression in osteoarthritic chondrocytes (all P < 0.0001). Silencing of RUNX-2 or FGF-23 did not affect SOX-9 mRNA levels in osteoarthritic chondrocytes. Moreover simultaneous down-regulation of SOX-9 and up-regulation of FGF-23 mRNA expressions in normal chondrocytes resulted in additive up-regulation of RUNX-2 mRNA expression. Treatment of normal chondrocytes with hrFGF-23 resulted in increased RUNX-2 mRNA expression, whereas it had no effect on SOX-9 mRNA expression. We demonstrated convincing associations among RUNX-2, SOX-9 and FGF-23 in relation to MMP-13 expression in osteoarthritic chondrocytes, contributing to a better understanding of the abnormal gene expression and cartilage degeneration processes associated with osteoarthritis.

Citing Articles

Therapeutic potential of SOX family transcription factors in osteoarthritis.

Huang Y, Wang Z Ann Med. 2025; 57(1):2457520.

PMID: 39887675 PMC: 11789227. DOI: 10.1080/07853890.2025.2457520.

Targeting Chondrocyte Hypertrophy as Strategies for the Treatment of Osteoarthritis.

Dong D, Jin G Bioengineering (Basel). 2025; 12(1).

PMID: 39851351 PMC: 11760869. DOI: 10.3390/bioengineering12010077.

Development of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling.

Zeng D, Umar M, Zhu Z, Pan H, Lu W, Xiao G Genes Dis. 2024; 12(1):101247.

PMID: 39552787 PMC: 11566674. DOI: 10.1016/j.gendis.2024.101247.

Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family.

Li H, Zhang J, Yuan D, Xie W, Ladel C, Mobasheri A Mil Med Res. 2024; 11(1):40.

PMID: 38902808 PMC: 11191355. DOI: 10.1186/s40779-024-00544-5.

Collagen type II solution extracted from supercritical carbon dioxide decellularized porcine cartilage: regenerative efficacy on post-traumatic osteoarthritis model.

Periasamy S, Chen Y, Hsu D, Hsieh D Bioresour Bioprocess. 2024; 11(1):21.

PMID: 38647941 PMC: 10992551. DOI: 10.1186/s40643-024-00731-1.

References

Ueta C, Iwamoto M, Kanatani N, Yoshida C, Liu Y, Enomoto-Iwamoto M . Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. J Cell Biol. 2001; 153(1):87-100. PMC: 2185519. DOI: 10.1083/jcb.153.1.87. View

Kent J, Wheatley S, Andrews J, Sinclair A, Koopman P . A male-specific role for SOX9 in vertebrate sex determination. Development. 1996; 122(9):2813-22. DOI: 10.1242/dev.122.9.2813. View

Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G . Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89(5):747-54. DOI: 10.1016/s0092-8674(00)80257-3. View

Gebhard P, Gehrsitz A, Bau B, Soder S, Eger W, Aigner T . Quantification of expression levels of cellular differentiation markers does not support a general shift in the cellular phenotype of osteoarthritic chondrocytes. J Orthop Res. 2003; 21(1):96-101. DOI: 10.1016/S0736-0266(02)00094-3. View

DAlonzo R, Selvamurugan N, Karsenty G, Partridge N . Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation. J Biol Chem. 2001; 277(1):816-22. DOI: 10.1074/jbc.M107082200. View

Aigner T, Gebhard P, Schmid E, Bau B, Harley V, Poschl E . SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes. Matrix Biol. 2003; 22(4):363-72. DOI: 10.1016/s0945-053x(03)00049-0. View

Kim J, Bae S, Choi J, Kim H, Ryoo H . The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem. 2002; 278(1):319-26. DOI: 10.1074/jbc.M203750200. View

Chin H, Fisher M, Li Y, Ferrari D, Wang C, Lichtler A . Studies on the role of Dlx5 in regulation of chondrocyte differentiation during endochondral ossification in the developing mouse limb. Dev Growth Differ. 2007; 49(6):515-21. DOI: 10.1111/j.1440-169X.2007.00940.x. View

Zhou G, Zheng Q, Engin F, Munivez E, Chen Y, Sebald E . Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci U S A. 2006; 103(50):19004-9. PMC: 1748167. DOI: 10.1073/pnas.0605170103. View

10.

Aigner T, Kim H . Apoptosis and cellular vitality: issues in osteoarthritic cartilage degeneration. Arthritis Rheum. 2002; 46(8):1986-96. DOI: 10.1002/art.10554. View

11.

Shum L, Nuckolls G . The life cycle of chondrocytes in the developing skeleton. Arthritis Res. 2002; 4(2):94-106. PMC: 128921. DOI: 10.1186/ar396. View

12.

Bridgewater L, Lefebvre V, de Crombrugghe B . Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer. J Biol Chem. 1998; 273(24):14998-5006. DOI: 10.1074/jbc.273.24.14998. View

13.

Sanchez C, He Y, Leiferman E, Wilsman N . Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism. Kidney Int. 2004; 65(5):1740-8. DOI: 10.1111/j.1523-1755.2004.00577.x. View

14.

Fukui N, Purple C, Sandell L . Cell biology of osteoarthritis: the chondrocyte's response to injury. Curr Rheumatol Rep. 2001; 3(6):496-505. DOI: 10.1007/s11926-001-0064-8. View

15.

Sabbagh Y, Carpenter T, Demay M . Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A. 2005; 102(27):9637-42. PMC: 1172249. DOI: 10.1073/pnas.0502249102. View

16.

Hollberg K, Marsell R, Norgard M, Larsson T, Jonsson K, Andersson G . Osteoclast polarization is not required for degradation of bone matrix in rachitic FGF23 transgenic mice. Bone. 2008; 42(6):1111-21. DOI: 10.1016/j.bone.2008.01.019. View

17.

Kamekura S, Kawasaki Y, Hoshi K, Shimoaka T, Chikuda H, Maruyama Z . Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum. 2006; 54(8):2462-70. DOI: 10.1002/art.22041. View

18.

Erlebacher A, Filvaroff E, Gitelman S, Derynck R . Toward a molecular understanding of skeletal development. Cell. 1995; 80(3):371-8. DOI: 10.1016/0092-8674(95)90487-5. View

19.

Solomon L, Berube N, Beier F . Transcriptional regulators of chondrocyte hypertrophy. Birth Defects Res C Embryo Today. 2008; 84(2):123-30. DOI: 10.1002/bdrc.20124. View

20.

Guo J, Chung U, Yang D, Karsenty G, Bringhurst F, Kronenberg H . PTH/PTHrP receptor delays chondrocyte hypertrophy via both Runx2-dependent and -independent pathways. Dev Biol. 2006; 292(1):116-28. DOI: 10.1016/j.ydbio.2005.12.044. View